Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Adavosertib CAS 955365-80-7 API Active Pharmaceutical Ingredient C27H32N8O2

Adavosertib CAS 955365-80-7 API Active Pharmaceutical Ingredient C27H32N8O2

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 955365-80-7

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:

Adavosertib CAS 955365-80-7

,

Adavosertib Active Pharmaceutical Ingredient

,

Adavosertib C27H32N8O2

CAS NO::
955365-80-7
Appearance::
Yellow Solid Powder
Molecular Formula::
C27H32N8O2
Molecular Weight::
500.59
EINECS NO::
680-342-0
MDL NO::
MFCD17215200
CAS NO::
955365-80-7
Appearance::
Yellow Solid Powder
Molecular Formula::
C27H32N8O2
Molecular Weight::
500.59
EINECS NO::
680-342-0
MDL NO::
MFCD17215200
Adavosertib CAS 955365-80-7 API Active Pharmaceutical Ingredient C27H32N8O2

Product Description:

Product Name: Adavosertib (MK-1775) CAS NO: 955365-80-7

 

Synonyms:

1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one;

2-allyl-1,8-dimethoxyanthracene-9,10-dione;

 

Chemical & Physical Properties:

Appearance: Yellow solid powder

Assay :≥99.0%

Density:1.293 g/cm3

Boiling Point:723.8℃ at 760 mmHg

Flash Point:391.5℃

Solubility: Soluble in DMSO.

 

MK-1775, also known as adavosertib, AZD-1775, is a WEE1 inhibitor, is also a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.